

REMARKS

The claims have been amended better to point out that which applicants regard as their invention, to overcome the rejections under the second paragraph of 35 USC 112, and to address the helpful suggestions of the Examiner in the Miscellaneous section of the Office Action at page 7.

The objection to the disclosure regarding the tables on pages 11, 13, and 14 is acknowledged. Enclosed herewith are replacement pages that do not contain non-English language characters. The Examiner is asked to telephone the undersigned if the Examiner is still having difficulty in clearly reading the chemical formulae in those tables.

Claims 8 and 11 were rejected under the second paragraph of 35 USC 112. The Examiner pointed out correctly that there was no definition of R^2 to R^{17} . The application has been amended to indicate that the term properly reads R^1 to R^{18} .

The Examiner had questioned the term "inactive to other compounds present in the organic light emitting layer" in claim 11. Claim 11 has been amended to depend from claim 2 and also to characterize the bis-condensed aromatic cyclic compound as one that does not take part in a recombination of electrons and holes or in the formation of an excited state.

Serial No. 09/993,660

Support for this change to the claim is found in the specification at page 9, lines 18 to 20.

The various matters in the miscellaneous section in the Office Action, kindly pointed out by the Examiner, have been addressed as well in this reply. The phrase "a same" has been changed to "the same" in all claims in which the former appears.

Claim 1 has been revised to read in Jepson form and also to indicate that the bis-condensed aromatic cyclic compound is a substance for suppressing crystallization and one that does not cause a defect portion to occur at 85°C for at least 200 hours during driving of the device. Support is found in the specification for this characterization of material on page 5, lines 16 to 22 and in Comparative Example 1.

The rejection of claims 1 to 4, 6, 8, 9, and 11 under 35 USC 102 as anticipated by Inoue et al. '308 is respectfully traversed.

The reference discloses the use of various phenylanthracene compounds as a blue light-emitting material in an organic electroluminescent (EL) device. There is no recognition or suggestion of using a bis-condensed aromatic cyclic compound for suppressing crystallization and in which

Serial No. 09/993,660

no defect portion will occur at 85°C for at least 200 hours during driving of the organic EL device.

The rejection of claims 1 to 5, 8, 9, and 11 under 35 USC 102 as anticipated by Sakai et al. EP '366 is also respectfully traversed. Again, the reference discloses various compounds used to provide blue light in an organic EL device but there is no recognition or suggestion of the use of the particular identified compounds as a crystallization suppressant as claimed herein.

The rejection of claims 1 to 11 under 35 USC 103 as unpatentable over Inoue et al. '308, further in view of Hosokawa et al. '949 is also respectfully traversed.

Both references describe various compounds useful as light emitting materials in organic EL devices. There is no contemplation or suggestion of using as a particular additive one that suppresses crystallization and causes no defect portion to occur at 85° for at least 200 hours during driving of the device.

The Examiner is thanked for acknowledging receipt of the certified copy of the priority document.

Serial No. 09/993,660

Reconsideration of the application is earnestly solicited.


Respectfully submitted,

PARKHURST & WENDEL, L.L.P.



Charles A. Wendel

Registration No. 24,453


Date

CAW/ch

Enclosure:

Copies of specification
pages 11, 13, and 14

Attorney Docket No.: OHTN:011

PARKHURST & WENDEL, L.L.P.
1421 Prince Street
Suite 210
Alexandria, Virginia 22314-2805
Telephone: (703) 739-0220



RECEIVED
JUN 11 2003
GROUP 1700









A2


Compound No.	R ²¹	R ²²	R ²³	R ²⁴	R ²⁵	R ²⁶	R ²⁷	R ²⁸	R ²⁹	R ³⁰
(4-1)	H	H	H	H	H	H	H	H	H	H
(4-2)	CH ₃	H	H	H	H	CH ₃	H	H	H	H
(4-3)	t-C ₄ H ₉	H	H	H	H	t-C ₄ H ₉	H	H	H	H
(4-4)	OCH ₃	H	H	H	H	OCH ₃	H	H	H	H
(4-5)	OPh	H	H	H	H	OPh	H	H	H	H
(4-6)	N(C ₂ H ₅) ₂	H	H	H	H	N(C ₂ H ₅) ₂	H	H	H	H
(4-7)	N(Ph) ₂	H	H	H	H	N(Ph) ₂	H	H	H	H
(4-8)	Ph	H	H	H	H	Ph	H	H	H	H
(4-9)		H	H	H	H		H	H	H	H
(4-10)	H	CH ₃	H	H	H	H	CH ₃	H	H	H
(4-11)	H	CH ₃	H	CH ₃	H	H	CH ₃	H	CH ₃	H
(4-12)	H	H	CH ₃	H	H	H	H	CH ₃	H	H
(4-13)	H	CH ₃	H	H	CH ₃	H	CH ₃	H	H	CH ₃
(4-14)	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃
(4-15)	t-C ₄ H ₉	H	H	H	H	H	H	H	H	H
(4-16)		H	H	H	H		H	H	H	H
(4-17)	H	Ph	H	H	H	H	Ph	H	H	H
(4-18)	H	H	Ph	H	H	H	H	Ph	H	H
(4-19)		H	H	H	H		H	H	H	H
(4-20)	n-C ₄ H ₉	H	H	H	H	n-C ₄ H ₉	H	H	H	H



RECEIVED
JUN 11 2003
GROUP 1700

A3

Compound No.	R ^{21'}	R ^{22'}	R ^{23'}	R ^{24'}	R ^{25'}	R ^{26'}	R ^{27'}	R ^{28'}	R ^{29'}	R ^{30'}
(5-1)	H	H	H	H	H	H	H	H	H	H
(5-2)	CH ₃	H	H	H	H	CH ₃	H	H	H	H
(5-3)	t-C ₄ H ₉	H	H	H	H	t-C ₄ H ₉	H	H	H	H
(5-4)	OCH ₃	H	H	H	H	OCH ₃	H	H	H	H
(5-5)	OPh	H	H	H	H	OPh	H	H	H	H
(5-6)	N(C ₂ H ₅) ₂	H	H	H	H	N(C ₂ H ₅) ₂	H	H	H	H
(5-7)	N(Ph) ₂	H	H	H	H	N(Ph) ₂	H	H	H	H
(5-8)	Ph	H	H	H	H	Ph	H	H	H	H
(5-9)		H	H	H	H		H	H	H	H
(5-10)	H	CH ₃	H	H	H	H	CH ₃	H	H	H
(5-11)	H	H	CH ₃	H	H	H	H	CH ₃	H	H
(5-12)	H	H	CH ₃	CH ₃	H	H	H	CH ₃	CH ₃	H
(5-13)	H	H	CH ₃	H	CH ₃	H	H	CH ₃	H	CH ₃
(5-14)	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃	CH ₃
(5-15)	H	Ph	H	H	H	H	Ph	H	H	H
(5-16)	H	H	Ph	H	H	H	H	Ph	H	H
(5-17)		H	H	H	H		H	H	H	H
(5-18)	t-C ₄ H ₉	H	H	H	H	H	H	H	H	H
(5-19)		H	H	H	H		H	H	H	H
(5-20)		H	H	H	H		H	H	H	H

[illegible]